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Abstract
Genomic alterations in cancer cells result in vulnerabilities that clinicians can exploit using molecularly targeted drugs,
guided by knowledge of the tumour genotype. However, the selective activity of these drugs exerts an evolutionary pressure
on cancers that can result in the outgrowth of resistant clones. Use of rational drug combinations can overcome resistance to
targeted drugs, but resistance may eventually develop to combinatorial therapies. We selected MAPK- and PI3K-pathway
inhibition in colorectal cancer as a model system to dissect out mechanisms of resistance. We focused on these signalling
pathways because they are frequently activated in colorectal tumours, have well-characterised mutations and are clinically
relevant. By treating a panel of 47 human colorectal cancer cell lines with a combination of MEK- and PI3K-inhibitors, we
observe a synergistic inhibition of growth in almost all cell lines. Cells with KRAS mutations are less sensitive to PI3K
inhibition, but are particularly sensitive to the combined treatment. Colorectal cancer cell lines with inherent or acquired
resistance to monotherapy do not show a synergistic response to the combination treatment. Cells that acquire resistance to
an MEK–PI3K inhibitor combination treatment still respond to an ERK–PI3K inhibitor regimen, but subsequently also
acquire resistance to this combination treatment. Importantly, the mechanisms of resistance to MEK and PI3K inhibitors
observed, MEK1/2 mutation or loss of PTEN, are similar to those detected in the clinic. ERK inhibitors may have clinical
utility in overcoming resistance to MEK inhibitor regimes; however, we ﬁnd a recurrent active site mutation of ERK2 that
drives resistance to ERK inhibitors in mono- or combined regimens, suggesting that resistance will remain a hurdle.
Importantly, we ﬁnd that the addition of low concentrations of the BCL2-family inhibitor navitoclax to the MEK–PI3K
inhibitor regimen improves the synergistic interaction and blocks the acquisition of resistance.
Introduction
Over recent years an improved understanding of the mole-
cular basis of cancer has led to the concept of precision
medicine, where treatment with targeted drugs is guided by
knowledge of the patient’s tumour genotype [1]. Although
this approach can be successful, the selective pressure that
targeted agents exert can result in the outgrowth of resistant
clones [2–5]. The molecular responses of tumours to ther-
apeutics targeting the MAPK pathway are paradigms for the
development of resistance [3, 4, 6]. Early studies of BRAF-
and MEK-inhibitors targeting this pathway established that
they were particularly active in BRAF mutant melanoma
[6–8]. However, even in this patient cohort, the response is
generally temporary with most patients relapsing within a
year [6]. To overcome resistance, an RAF–MEK inhibitor
combination has been approved for the treatment of mutant
BRAF melanoma and, more recently, has been shown to be
effective in BRAF mutant colorectal cancer [9–12]. How-
ever, despite improved responses to these combination
therapies tumours still recur [12, 13].
Colorectal cancers frequently have genetic aberrations in
the MAPK or phosphatidylinositol 3-kinase (PI3K) path-
ways [14] and targeting these pathways can inhibit tumour
growth [7, 15–17]. However, a signiﬁcant proportion of
colorectal tumours have genetic abnormalities that activate
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both pathways [14], resulting in a reduced response
to monotherapy. The interconnectedness of these two
pathways suggests that combination of MEK- and PI3K-
inhibitors is a rational therapeutic approach. Several studies
have explored combinations of MEK- and PI3K-inhibitors
in vivo and in vitro and have reported both positive and
negative effects of the combination treatment versus
monotherapy [16, 18–21].
It is important to understand the mechanisms responsible
for resistance to targeted cancer drugs to inform their future
clinical use. In this study we focus on colorectal cancer and
ﬁnd that a combination of MEK- and PI3K-inhibitors is
synergistic for growth inhibition across a panel of human
colorectal cell lines, particularly in KRAS mutant cells with
a reduced sensitivity to PI3K inhibition. We also ﬁnd that
prolonged exposure to a PI3K inhibitor plus an MEK- or
ERK-inhibitor leads to the emergence of resistance;
importantly, however, this resistance can be overcome by
cotreatment with a BCL2-family inhibitor.
Results
MEK- and PI3K-inhibitors act synergistically in
human colorectal cancer cells
Initially, we determined the potency of PI3K pathway
inhibitors in a panel of 29 human colorectal cancer cell
lines, in order to aid selection of exemplars for further
analysis (Supplementary Table 1–2; Supplementary Fig. 1).
To determine the relationship between inhibitor selectivity
proﬁle and its ability to block PI3K signalling, we also
measured AKT phosphorylation in HCT116 human color-
ectal cancer cells (Fig. 1a), including additional PI3K
Fig. 1 Synergistic inhibition of HCT116 human colorectal cancer cell
growth by MEK and PI3K inhibitors. a Comparison of the EC50 for
inhibition of AKTSER473 and AKTTHR308 phosphorylation with the GI50
of PI3K inhibitors (EC50 values, n= 2) using an electro-
chemiluminescent ELISA. b, c Effect on HCT116 cell growth of 96 h
exposure to pictilisib (pan-PI3K inhibitor) and cobimetinib (MEK
inhibitor). d Effect of CCT245731 (an inactive analogue of pictilisib)
and cobimetinib (Supplementary Tables S1-2) or single/repeated
treatment with cobimetinib. e Combination indices for combination
treatments featuring PI3K pathway inhibitors with different selectivity
proﬁles. Column colours indicate PI3K pathway inhibitor selectivity:
orange= pan-class I, cyan= class I isoform-selective, red= dual
mTOR–pan-class I, blue=mTOR. The pink region indicates CI
values associated with an additive effect, determined by combining
two doses of cobimetinib (from (d)). Mean values (s.e.m.), n ≥ 3
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pathway inhibitors to widen the analysis. For the majority of
the inhibitors the EC50 values for inhibition of AKT
SER473
and AKTTHR308 phosphorylation are similar and correlate
with GI50 values for cell growth inhibition (Fig. 1a). The
mTOR-selective inhibitors and one of the dual mTOR–pan
class I PI3K inhibitors, dactolisib, are an exception, with
disparate EC50 values for inhibition of AKT
SER473 and
AKTTHR308 phosphorylation (Fig. 1a).
We next used HCT116 and SW480 colorectal cancer cell
lines, initially with the cobimetinib (MEK inhibitor; Sup-
plementary Table 3) and pictilisib (class I PI3K inhibitor) to
establish the combination methodology. We observe a
synergistic interaction with CI values of 0.515 ± 0.030 and
0.305 ± 0.026 respectively at the combination EC50 (Fig. 1b,
c; Supplementary Fig. 2a). As controls, substituting picti-
lisib with CCT245731 (an inactive analogue [15, 22];
Supplementary Table 1) eliminates the synergistic response
(Fig. 1d), while a combination of cobimetinib with a second
treatment of cobimetinib, predicted to give an additive value
of 1, results in a measured CI of 1.241 ± 0.146 (Fig. 1d).
Having established that we could detect a synergistic
interaction, we tested a selection of MEK inhibitors with
different PI3K-pathway inhibitors in HCT116 and SW480
cells (Supplementary Tables 1 and 3). Combinations of all
three MEK inhibitors, PD0325901, cobimetinib or selu-
metanib with pictilisib gave synergistic inhibition of cell
growth (Fig. 1e). Similarly, all three pan-class I PI3K
inhibitors, pictilisib, ZSTK474 and taselisib are equally
synergistic with the MEK inhibitor cobimetinib. Alpelisib,
which is highly selective for the alpha-isoform of PI3K, is
the most effective of all of the isoform-speciﬁc PI3K inhi-
bitors tested in combination with cobimetinib, producing
effects equivalent to the pan-class I PI3K inhibitors. The
dual mTOR–pan-class I PI3K inhibitors apitolisib, PI-103
and dactolisib are less effective than their pan-class I PI3K-
selective counterparts when used in combination with
cobimetinib. As previously described [21], we found that
combining any of the mTOR-speciﬁc inhibitors, AZD8055,
torkinib or WYE125132, with cobimetinib results in an
additive, rather than synergistic, response in both lines (Fig.
1e; Supplementary Fig. 2b).
Based on their cell panel GI50 potency, activity against
AKT phosphorylation and combination efﬁcacy (Fig. 1;
Supplementary Fig. 1–2), we selected the pan-class I PI3K
inhibitor pictilisib and the MEK inhibitor cobimetinib for
use in subsequent experiments to explore the basis of
resistance to combined MEK−PI3K inhibitor treatment.
Combined MEK- and PI3K-inhibition induces
apoptosis
Monotherapy with either cobimetinib or pictilisib does not
induce apoptosis biomarkers, whereas monotherapy with
the pictilisib alone increases the level of LC3B, potentially
indicative of autophagy (Fig. 2a, b). In contrast, the com-
bination treatment induces apoptosis-associated caspase
activation in both HCT116 and SW480 cells with no
detectable autophagy-associated LC3B signal (Fig. 2a, b;
Supplementary Fig. 2c).
We used an siRNA minipanel to identify regulators of
the apoptotic response induced by the combination regimen.
At least 2/3 of the siRNAs targeting the expression of
antiapoptotic BCLXL and MCL1 induced apoptotic caspase
activity. In contrast, siRNA silencing of proapoptotic genes
BIM, BBC3, BID and BAX signiﬁcantly reduces
combination-induced apoptosis (Fig. 2c). We conﬁrmed
that BAX and BBC3 are required for the induction of
apoptosis by the combination treatment using isogenic
knockout HCT116BAX−/− and HCT116BBC3−/− cell lines
(Fig. 2d) [23, 24]. Interestingly, the cobimetinib–pictilisib
combination treatment retains its synergistic activity in both
knockout lines (HCT116BAX−/− CI= 0.518 ± 0.035,
HCT116BBC3−/− CI= 0.604 ± 0.035), indicating that apop-
tosis deﬁned by caspase activation is not exclusively
required for these inhibitors to act in synergy.
Combined MEK- and PI3K-inhibition acts
synergistically on RPS6 phosphorylation and
Forkhead-regulated gene expression
Next, we determined the molecular response to combined
MEK- and PI3K-inhibition and observe a decrease in the
levels of phosphorylated ERK and AKT (Fig. 3a; Supple-
mentary Fig. S3a). However, the combination treatment is
no more effective at inhibiting ERK or AKT phosphoryla-
tion than the single treatments. Similarly, the combination
treatment is no more effective at inhibiting 4E-BP1 phos-
phorylation (Fig. 3a; Supplementary Fig. 3a) or global cap-
dependent protein synthesis than monotherapy (Fig. 3b;
Supplementary Fig. 3b). In contrast, we observe a sig-
niﬁcant synergistic reduction in the level of phosphorylated
RPS6 following combination treatment, compared to levels
after monotherapy (HCT116 CI= 0.268 ± 0.023; SW480
CI= 0.395 ± 0.066; P < 0.05; Fig. 3a; Supplementary
Fig. 3a).
Levels of transcript for two Forkhead-regulated genes,
KLHL24 and CCNG2 [25], are signiﬁcantly increased
by the combination treatment (Fig. 3c; Supplementary
Fig. 4a). This contrasts with genes regulated by the
individual PI3K (CDC6 and MCM10) or MAPK (DUSP6
and SPRY4) pathways [7, 25] or encoding proapoptotic
factors (BIM, BBC3 and BID) (Fig. 3d; Supplementary
Fig. 4b-c). BBC3 and BIM are also induced at the protein
level by pictilisib and cobimetinib monotherapy respec-
tively, but not further induced by the combination (Sup-
plementary Fig. 4b).
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MEK- and PI3K-inhibitor combination treatment has
a synergistic effect in multiple colorectal cell lines
To determine CI values in our panel of 47 human colorectal
cancer cell lines we ﬁrst established GI50 values for cobi-
metinib, pictilisib or the dual mTOR–pan-class I PI3K
inhibitor apitolisib (Supplementary Fig. 5). We observe that
KRAS-mutant PIK3CA-wild-type cells are signiﬁcantly less
sensitive to the PI3K inhibitor pictilisib than the wild type
(P= 0.019, q= 0.0498) or KRAS-wild-type PIK3CA-
mutant cells (P= 0.0076, q= 0.0384). Cells with KRAS
codon 12 mutations (KRASCDN12/PIK3CAWT) are the least
sensitive to PI3K inhibition overall (P= 0.0051, q=
0.0108; Supplementary Fig. 5). Most BRAF mutant cell
lines are very sensitive to the MEK inhibitor cobimetinib
compared to wild-type cells (BRAFMUT P= 0.0487, q=
0.0804; BRAFMUT/PIK3CAMUT P= 0.0085, q= 0.0281).
We ﬁnd that the interaction between cobimetinib and
pictilisib is synergistic in all but one colorectal cell line,
with CI values ranging from 0.296 to 0.884 (Fig. 4a; Sup-
plementary Table 4). There is a strong synergistic response
(CI < 0.5) to the combination treatment in many KRAS
mutant lines, but this is not statistically signiﬁcant across
the whole panel (Supplementary Fig. 6a). As observed with
the HCT116 and SW480 cell lines, the synergistic effect of
the combination treatment is reduced when the dual
mTOR–PI3K inhibitor apitolisib is used in place of picti-
lisib (Supplementary Fig. 6b).
The growth of COLO320 cells is insensitive to MEK
inhibition (cobimetinib GI50= 1455 nM; Supplementary
Fig. 2 BAX, BBC, BID and BIM mediate apoptosis in HCT116
human colorectal cancer cells subjected to combined MEK–PI3K
inhibition. Levels of a LC3 staining, indicative of autophagy, and b
caspase activity, indicative of apoptosis, following 24 h treatment with
cobimetinib and/or pictilisib. c Caspase 3/7 activity following trans-
fection of cells with siRNA against proapoptotic genes for 48 h and
subsequent treatment with 5× GI50 cobimetinib and pictilisib, or the
vehicle control, for 24 h. Caspase activity is expressed relative to that
in cells treated with Allstars negative control siRNA (*P ≤ 0.001). d
Caspase activity in the HCT116 parental cells and HCT116BBC3−/− or
HCT116BAX−/− cell lines after a combined treatment with cobimetinib
and pictilisib. All plots show mean values (s.e.m.), n ≥ 3
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Table 4) and shows no evidence of synergy with the com-
bination. We also ﬁnd that SW620 cells (lymph node
metastasis)—which are derived from the same patient as
SW480 cells (primary tumour) (Fig. 4b)—are less sensitive
to pictilisib (Supplementary Fig. 6c) and also to the cobi-
metinib–pictilisib combination (SW480 CI= 0.310 ± 0.018,
SW620 CI= 0.596 ± 0.017, P < 0.001). Consistent with
this, the combined MEK–PI3K inhibitor treatment of
SW620 cells does not induce apoptosis and has no addi-
tional effect on RPS6 phosphorylation or Forkhead-
regulated gene expression (Fig. 4c, d; Supplementary
Figs. 2c, 3, 4a and 6c).
Overall, across the large panel of colorectal cell lines
with a range of genetic backgrounds, combined MEK- and
PI3K-inhibition is highly synergistic, particularly in KRAS
mutant cancers. In addition, we ﬁnd that inherent resistance
or reduced sensitivity to the MEK−PI3K inhibitor combi-
nation is rare, but can result from reduced or loss of sen-
sitivity to either arm of the combination therapy.
Cells with acquired insensitivity to MEK- or PI3K-
inhibitor monotherapy are also resistant to
combination therapy
We found that some cells that survived 7 days exposure to
the combination treatment were able to proliferate when
fresh drug-free medium was added (Fig. 5a). To dissect out
potential resistance mechanisms, we ﬁrst examined cells
Fig. 3 Combined MEK–PI3K inhibition has a synergistic effect on
RPS6 phosphorylation and FOXO-regulated transcription in HCT116
human colorectal cancer cells. a Expression of phospho- or total
proteins following 6 h exposure to cobimetinib and/or pictilisib. b
Level of cap-dependent protein synthesis initiation (ﬁreﬂy luciferase)
after 24 h exposure to cobimetinib and/or pictilisib. Data normalised to
cap-independent protein synthesis initiation (EMCV IRES-driven
renilla luciferase expressed from the same bicistonic mRNA) and
expressed relative to vehicle control. c Transcript abundance deter-
mined by RT-PCR after 14 h exposure to cobimetinib and/or pictilisib
(*P ≤ 0.001). All data are mean values (s.e.m) shown relative to that
for cells treated with the vehicle control (n ≥ 3)
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with acquired resistance to the individual elements of the
combined regimen. Exposure of HCT116 cells to increasing
concentrations of MEK or PI3K inhibitors over a period of
8–10 weeks generated an MEK inhibitor resistant line
(HCT116MEKRES) with a GI50 for cobimetinib (401 ± 55
nM) 13-fold greater than that of the parental line and also a
PI3K inhibitor resistant line (HCT116PI3KRES) with a GI50
for pictilisib (3119 ± 266 nM; Fig. 5b) 5-fold greater than
that of the parent line. HCT116MEKRES cells fail to show a
synergistic response to the combination treatment, even
when the concentration of cobimetinib used is increased
(Fig. 5b). Treating HCT116PI3KRES cells with a concentra-
tion of cobimetinib and pictilisib that is effective on the
parental cells does not result in a synergistic inhibition of
cell growth but, in contrast to the HCT116MEKRES cells,
there is a synergistic response to the combination treatment
when a ﬁvefold higher concentration of pictilisib is used
(CI= 0.589 ± 0.026; Fig. 5b).
Whole-exome sequencing showed that >92% of the
single nucleotide variants (SNV) and insertions or deletions
(INDELS) were conserved between the parent and resistant
cells, conﬁrming that the two resistant lines were derived
from parent HCT116 cells (Fig. 5c). Among the variants
unique to the HCT116PI3KRES cells are two frameshift
mutations in PTEN (PTENK14fs* and PTENN323fs*).
Sequencing of PTEN cDNA clones isolated from
HCT116PI3KRES cells detected only mutant cDNAs (Sup-
plementary Fig. 7), consistent with the loss of PTEN protein
and elevated phosphorylation of AKTSER473 (Fig. 5d) that
still remains sensitive to pictilisib treatment at high con-
centrations (Fig. 5f), explaining the synergistic response to
the combination treatment at high pictilisib concentrations.
Exome sequencing of HCT116MEKRES identiﬁed a
MEK1L215P mutation previously detected in other MEK
inhibitor resistant cell lines or patients that prevents MEK
inhibitor binding [26]. These HCT116MEKRES cells are
cross-resistant to the MEK inhibitors selumetanib (GI50 >
2000 nM) and trametinib (Supplementary Fig. 8a and
Supplementary Table 3) but remain sensitive to the ERK
inhibitor VTX11e [27] and to VTX11e–pictilisib combi-
nation therapy (CI= 0.551 ± 0.028), indicating that the
MEK–ERK pathway is still required by HCT116MEKRES
cells (Fig. 5e). ERK1/2 phosphorylation is less responsive
to cobimetinib treatment in the HCT116MEKRES cell line,
consistent with the inability of cobimetinib to bind mutated
MEK (Fig. 5f).
Sustained combination treatment results in the
acquisition of resistance
We next cultured HCT116 colorectal cancer cells in
increasing concentrations of cobimetinib and pictilisib and
ﬁnd they acquired resistance to the combination treatment
over a period of 8–10 weeks. This resistance is due to
reduced sensitivity to MEK inhibition (Fig. 6a, b). As
observed for HCT116MEKRES, we ﬁnd that the combination-
Fig. 4 Combined MEK–PI3K inhibitor treatment is synergistic across
a human colorectal cancer panel. a GI50 values for pictilisib versus
cobimetinib in each cell line, determined after a 96 h treatment; data
point size denotes the CI value, range: 0.296−0.884 (inverse corre-
lation). b Venn diagram showing the number of SNVs detected in
HCT116, SW480, and SW620 human colorectal cancer cell lines that
are predicted to alter protein sequence. c Levels of caspase 3/7 activity,
indicative of apoptosis, in SW620 cells exposed to pictilisib or cobi-
metinib for 24 h. d Transcript abundance in SW620 cells exposed to
pictilisib and/or cobimetinib for 6 h. Mean levels (s.e.m.) are shown
relative to those in cells treated with a vehicle control (n ≥ 3)
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resistant HCT116DUALRES cells are cross-resistant to selu-
metanib (GI50 > 2000 nM) and trametinib (Supplementary
Fig. 8a). Replacing the MEK inhibitor cobimetinib arm of
the combination treatment with the ERK inhibitor VTX11e
(Fig. 6c) restores synergy (CI= 0.693 ± 0.034 nM), indi-
cating that a dependence on signalling downstream of MEK
still remains. Importantly, exposure of the HCT116DUALRES
line to increasing concentrations of VTX11e and pictilisib
subsequently resulted in the acquisition of resistance to this
combination treatment as a result of loss of sensitivity to
VTX11e at the level of ERK1/2 (Fig. 6c, d). This cell line
(HCT116DUALERKRES) retains resistance to the original
cobimetinib–pictilisib combination (Supplementary Fig. 8b).
Subsequently, we generated HCT116 cells with acquired
resistance to ERK inhibitor monotherapy (HCT116ERKRES;
Fig. 6f), which unlike the HCT116DUALERKRES line, is sensi-
tive to MEK inhibition—consistent with derivation from the
parent HCT116 cells (Supplementary Fig. 8c).
Exome sequencing conﬁrmed that the combination- and
VTX11e-resistant lines (HCT116ERKRES, HCT116DUALRES
and HCT116DUALERKRES) are also derived from parental
HCT116 cells (Fig. 6f). HCT116DUALRES had acquired an
MEK2V215E mutation that prevents inhibitor binding, ana-
logous to that detected in HCT116MEKRES cells. We found
that HCT116DUALERKRES also shared 644 variants with
HCT116DUALRES cells, including the MEK2V215E mutation,
consistent with its derivation from HCT116DUALRES. In
addition, HCT116DUALERKRES cells acquired 114 unique
variants including an ERK2Y36H mutation. The ERK2Y36H
mutation is also detected in the HCT116ERKRES cells.
Fig. 5 HCT116 human colorectal cancer cells resistant to MEK or
PI3K inhibitor monotherapy are insensitive to combination treatment.
a Photographs of HCT116 cells treated with 5× GI50 cobimetinib and/
or pictilisib. b Fraction of HCT116MEKRES or HCT116PI3KRES cells
surviving 96 h exposure to pictilisib and/or cobimetinib. c Venn dia-
gram showing the number of SNVs or INDELs predicted to alter
protein sequence in HCT116, HCT116MEKRES and HCT116PI3KRES
cells. d Immunoblot indicating the abundance of PTEN, pAKTSER473
and total AKT in two independent cultures of HCT116 and
HCT116PI3KRES cells. e Fraction of cells surviving 96 h exposure to
VTX11e. f Mean levels (s.e.m.) of pERK1THR202/TYR204 and
pERK2THR185/TYR187, pAKTSER473, total ERK1/2 and total AKT after 6
h exposure to drug or a vehicle control (n ≥ 3)
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Consistent with their derivation from the parent cells, the
HCT116ERKRES cells lack the MEK2V215E mutation and the
additional sequence variants found in HCT116DUALRES and
HCT116DUALERKRES cells.
The Y36H mutant found in ERK inhibitor resistant
cells is insensitive to ERK inhibitors
Next, we determined the functional impact of the ERK2Y36H
mutation. The values of Km and Vmax found for ATP cor-
responding to ERK2WT and ERK2Y36H enzymes are similar
(Supplementary Fig. 9a). ERK2Y36H exhibited 19-fold
resistance to VTX11e, 5-fold resistance to the ERK inhi-
bitor ravoxertinib [28] and 2.7-fold resistance to
SCH772984, a chemically distinct ERK1/2 inhibitor (Fig.
7a, Supplementary Fig. 9a-b; Supplementary Table 5) [29].
The differential resistance of the ERK2Y36H protein to these
inhibitors reﬂects the activity of the inhibitors in
HCT116DUALERKRES and HCT116ERKRES cells, with a
hierarchy of fold-resistance in the order of VTX11e >
ravoxertinib > SCH772984 (Supplementary Fig. 10).
HCT116DUALERKRES and HCT116ERKRES cells are also
resistant to ulixertinib, a VXT11e derivative undergoing
clinical studies, but not to the mechanistically distinct DEL-
22379, which targets ERK dimerisation (Supplementary
Fig. 10) [30–32].
Modelling of the ERKY36H mutation using published X-
ray structures suggests that repulsion between the electron-
dense imidazole ring of H36 and the partial negative charge
of the aryl chlorine in VTX11e, also found in ulixertinib
and ravoxertinib, predicted to make binding to ERK2Y36H
unfavourable (Supplementary Fig. 11a-c) [27, 28, 33]. The
aryl chlorine is essential for the selectivity of VTX11e for
ERK2 over other kinases (Supplementary Table 2). In
contrast, this mutation is predicted to have little effect on
the binding of SCH772984 to ERK2, as both Y36 or H36
are predicted to fold under the active site P-loop
Fig. 6 Characterisation of HCT116 human colorectal cancer cells with
acquired resistance to MEK or ERK inhibitor-based combination
therapy. a Surviving fraction of HCT116DUALRES cells treated with
pictilisib and/or cobimetinib for 96 h. b Level of pERK1THR202/TYR204/
pERK2THR185/TYR187 in HCT116DUALRES cells exposed to pictilisib or
cobimetinib for 6 h. Data are shown relative to levels in cells treated
with a vehicle control. c Surviving fraction of HCT116DUALRES and
HCT116DUALERKRES cells after 96 h exposure to pictilisib and
VTX11e. d Levels of total and phospho-SER380 p90RSK following
treatment of HCT116 and HCT116DUALERKRES with VTX11e for 6 h. e
Surviving fraction of HCT116ERKRES cells after 96 h treatment with
pictisilib and/or VTX11e. f Venn diagram showing the number of
SNVs or INDELs predicted to alter protein sequence in HCT116,
HCT116MEKRES, HCT116DUALRES, HCT116DUALERKRES and
HCT116ERKRES cells. For all plots n ≥ 3 and error bars indicate s.e.m.
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(Supplementary Fig. 11d-e), explaining why ERK2Y36H
cells are only slightly less sensitive to SCH772984 than
wild type.
Exogenous expression of ERK2WT or ERK2Y36H results
in the parent HCT116 cells increased ERK2 phosphoryla-
tion, but decreased phosphorylation of endogenous ERK1
(Fig. 7b). Cells expressing exogenous ERK2WT or
ERK2Y36H retain their sensitivity to MEK inhibition by
cobimetinib (Fig. 7c). Expression of ERK2WT slightly
increases the VTX11e GI50, consistent with ERK2 ampli-
ﬁcation driving ERK inhibitor resistance [34] (HCT116,
113 ± 15 nM; HCT116-ERK2WT, 198 ± 30 nM); in contrast,
cells expressing ERK2Y36H are resistant to VTX11e (GI50 >
500 nM; Fig. 7c). Simultaneous depletion of ERK1/2
mRNA using siRNA affects the growth of HCT116 and
HCT116DUALERKRES cells equally and sensitised both lines
to cotreatment with pictilisib (Fig. 7d, e). This indicates that
the HCT116DUALERKRES line remains susceptible to com-
bined inhibition of MEK/ERK and PI3K, consistent with
acquired resistance mutations in ERK2 and MEK2 that
affected inhibitor binding but not enzymatic activity.
BCL2-family inhibitor blocks the acquisition of
resistance to MEK–PI3K combination treatment
BCL2-family inhibitors can act synergistically with MEK-
or PI3K-inhibitors [35–37], and also block the acquisition
of resistance to MEK inhibition [38]. We ﬁnd that BCLXL
siRNA induced apoptosis when combined with pictilisib
and cobimetinib (Fig. 2c). These observations prompted us
to expose HCT116 cells to a cobimetinib−pictilisib com-
bination treatment plus the BCL2-family inhibitor navito-
clax. Cotreatment with navitoclax (GI50= 7362 ± 247 nM)
improves the CI for pictilisib plus cobimetinib in HCT116
cells (CI= 0.406 ± 0.037), potentially by acting in synergy
both with pictilisib (CI= 0.552 ± 0.080) and cobimetinib
(CI= 0.636 ± 0.042; Fig. 8a). This effect was less pro-
nounced when pictilisib was replaced with the dual mTOR/
pan-class I PI3K inhibitor apitolisib (Supplementary Fig.
12a). We also found that addition of a ﬁxed concentration of
navitoclax increases sensitivity to the cobimetinib–pictilisib
combination in HCT116 cells (2500 nM navitolcax CI=
0.290 ± 0.021; 750 nM navitoclax CI= 0.387 ± 0.043; Fig.
Fig. 7 The ERK2Y36H mutation does not affect MAPK-pathway sig-
nalling but induces resistance to small molecule ERK inhibitors. a
Effect of VTX11e on ERK2 kinase activity. b Abundance of ERK2,
pERK1/2 and total ERK1/2 in the parental HCT116 line, drug
combination-resistant HCT116DUALERKRES line and recombinant lines
overexpressing ERK2WT or ERK2Y36H. c Fraction of HCT116 and
ERK2-overexpressing cells surviving 96 h treatment with cobimetinib
or VTX11e. d Level of ERK2 and ERK1/2 in cells transfected with
siRNA targeting ERK1/2 expression (C=mock control, N=Allstars
negative control nontargeting siRNA; ERK1 siRNA nos. 6, 7, 8, 11
and ERK2 siRNA nos. 10, 11, 12, 13; Qiagen, Germany). e Fraction of
HCT116 or HCT116DUALERKRES cells surviving 96 h exposure to
pictilisib after siRNA knockdown of ERK1/2 expression for 48 h prior
to drug treatment. For all data n= 3 and, where applicable, error bars
indicate s.e.m. GADPH was used as a loading control in immunoblots
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8b). HCT116DUALRES cells with previously acquired resis-
tance to the combined MEK−PI3K inhibitor regimen
through loss of sensitivity to MEK inhibition retained the
synergistic interaction between pictilisib and navitoclax, but
that was not further improved by the addition of cobimeti-
nib (Supplementary Fig. 12b). In the HCT116DUALRES cells,
replacement of cobimetinib with the ERK inhibitor VTX11e
rescued the potent synergistic activity of the triple combi-
nation, but again synergy was lost in HCT116DUALERKRES
cells with previously acquired resistance to the ERK inhi-
bitor combination regimen (Supplementary Fig. 12c-e).
Importantly, in longer-term clonogenic assays, we ﬁnd that
cotreatment with 750 nM navitoclax reduced the number of
HCT116 and SW480 cells surviving 7 days exposure to the
cobimetinib–pictilisib combination, such that we were
unable to generate stable clones with acquired resistance in
longer-term cultures (Fig. 8c, d).
Discussion
Combination treatment regimens have several advantages
over monotherapy: they may increase antitumour effects
within acceptable toxicity limits, are more likely to be
effective against a heterogeneous tumour population and
may delay or block the development of drug resistance [39].
Here, we used a panel of human colorectal cancer cell lines
to explore response to mono- and combination-therapies
targeting MEK and PI3K. Initial sensitivity proﬁling work
was followed up with a focused strategy using a single
colorectal cancer cell line model to identify mechanisms of
resistance. While the latter approach may not deﬁne the full
spectrum of resistance in colorectal cancer, we did ﬁnd
resistance mechanisms, namely loss of PTEN and mutation
of MEK1/2, that were previously reported in clinical
resistance to MEK and PI3K inhibitors [26, 40], thus vali-
dating the approach.
Our results indicate that MEK–PI3K inhibitor combina-
tion treatment affects multiple nodes at the intersection of
the MAPK and PI3K signalling pathways; these include
reduced RPS6 phosphorylation and induced Forkhead-
regulated gene expression [25]. RPS6 is phosphorylated
by p70 and p90 S6 kinases, which are themselves regulated
by MAPK and PI3K signalling, while the localisation and
stability of the Forkhead transcription factors is regulated
by AKT and ERK-mediated phosphorylation respectively
Fig. 8 Navitoclax administration prevents cells acquiring resistance to
a pictilisb–cobimetinib combination treatment. a Three-way combi-
nation treatment of HCT116 cells with cobimetinib, pictilisib and
navitoclax at 1:1:1 ratios of their respective GI50s. b Combination
treatment of HCT116 and SW480 cells with cobimetinib and pictilisib
at a 1:1 ratio of their respective GI50s ± a low ﬁxed concentration of
navitoclax. For all plots (a, b) data are mean (s.e.m.) values, n ≥ 3. c, d
Photographs of c HCT116 and d SW480 cells treated with 5× GI50
pictilisib–cobimetinib (combination treatment) or the combination
treatment ± 750 nM navitoclax. Cells were seeded in duplicate six-well
plates for 2 d before 7 d drug treatment or 7 d drug treatment plus a
further 5 d in drug-free media
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[41–43]. Whether or not the overall synergistic effect of
combined MEK- and PI3K-inhibition requires activity at
multiple nodes, or just at one critical node, remains to be
determined. We also ﬁnd that BIM, BBC3 and BAX are
required for the combination treatment to induce apoptosis,
in line with previous studies [35, 44]; however, apoptosis
measured by apoptotic protease activation is itself not
essential for synergy since we observe that isogenic BBC3
or BAX knockout cells retained the synergistic growth
inhibition response to MEK−PI3K inhibitors in the absence
of caspase activation.
We ﬁnd the selectivity proﬁle of the PI3K inhibitor
impacts the effectiveness of the combination regimen, as
mTOR, dual mTOR–PI3K inhibitors and PI3K-inhibitors
lacking activity against PIK3CA or poor potency against
AKTTHR308 phosphorylation have reduced synergy in com-
bination with MEK inhibition. The consistency of these
observations across multiple PI3K inhibitors, the majority of
which have been clinically tested, suggests that other PI3K
pathway inhibitors that can inhibit the class I alpha-isoform
but lack MTOR inhibitory activity, such as copanlisib
recently licensed for the treatment of follicular lymphoma
[45], will have a similar activity proﬁle in combination
regimes. Almost all of the 47 human colorectal cancer cell
lines tested exhibit a synergistic response to the optimal
MEK−PI3K inhibitor combination treatment. However,
colorectal cancer cell lines with inherent or acquired resis-
tance to either of the treatment arms exhibit a reduced
synergistic response to the combination regimen. Impor-
tantly, by exposing sensitive parent HCT116 cells to com-
bination treatments for a prolonged period we generated cell
lines that had lost the synergistic response that was initially
exhibited to the MEK–PI3K combination, and subsequently
also to the ERK–PI3K inhibitor combination that was at ﬁrst
able to overcome the resistance to the original MEK–PI3K
combination. In both cases, loss of synergy is associated
with the appearance of MEK and ERK mutations that were
predicted or shown to disrupt inhibitor binding [26, 46]
without overtly affecting MEK/ERK activity.
In contrast, resistance to PI3K inhibitor monotherapy
was found to involve pathway deregulation through loss
of PTEN, which we found can be overcome with higher
concentrations of PI3K inhibitor. The absence of muta-
tions preventing inhibitor binding to the PIK3CA lipid
kinase domain may reﬂect the fact that these types of
mutation are not well tolerated, because they tend to also
inhibit enzyme activity [47]. This suggests that combi-
nation resistance-inducing mutations preferentially occur
in MEK1/2 or ERK2 because mutations that disrupt
inhibitor binding are better tolerated in these targets and
do not affect enzymatic activity. Alternatively, or in
addition, the parent HCT116 cell line used in this study is
highly dependent on MAPK signalling, and disrupting
this pathway has a greater impact on the efﬁcacy of the
combination regimen.
ERK inhibitors are in early clinical studies, including
trials to determine if these agents can rescue resistance to
BRAF- and MEK-inhibitors [32, 48, 49]. In addition to
our own observations, studies expressing exogenously
mutated forms of ERK, or exposing cell lines to ERK
inhibitors, have identiﬁed mutations associated with
resistance to ERK inhibitors [34, 50, 51]. Interestingly, a
recent computational approach to identify resistance
mutations likely to arise following drug treatment predicts
mutation of ERK2Y36 as one of a number of mutation
hotspots generating resistance to ERK inhibition [52].
Together, those studies and our own data suggest that
resistance to ERK inhibitors may be inevitable in the
clinic and that switching the inhibitor may delay, but will
not avoid, the emergence of resistance.
Overall, we clearly show that a combination treatment
targeting the MEK- and PI3K-pathways is insufﬁcient to
block the acquisition of resistance in human colorectal
cancer cell line models, but the addition of a third agent, a
BCL2 inhibitor, is able to do this. Several studies have
shown that addition of a third agent can overcome acquired
resistance or enhance the combinatorial effect of single
agent MAPK- and PI3K-inhibitor regimens [53–55]. These
observations suggest that the addition of a third agent, in
our case a BCL2-family inhibitor, to create triple combi-
nations may generate a ﬁtness threshold that is too high to
surpass by resistance mechanisms involving gene mutation
or ampliﬁcation. Importantly, the synergistic effect of the
three-way combination was lost in cells with prior acqui-
sition of resistance to one arm of the combination, sug-
gesting that the triple therapy strategy is better suited to
preventing the acquisition of resistance rather than over-
coming existing intrinsic or acquired resistance from prior
treatment. Preclinical studies have established a strong
rationale for combined inhibition of PI3K- and MAPK-
pathways and numerous early clinical studies exploring this
approach are either in progress or completed [56]. Results
presented as meeting abstracts generally report only modest
activity of the combinations, often limited by toxicity [56].
Hence the addition of a third agent, while potentially ben-
eﬁcial, would require careful consideration of tolerability. It
is feasible that short exposures to higher concentrations may
have similar or greater antitumour activity while being
better tolerated than continuous exposures to lower doses.
For example, short intermittent exposures to a MEK-PI3K
inhibitor combination treatment are sufﬁcient to drive an
in vivo response in preclinical models [16, 53]. Thus it is
possible that the addition of a third agent may be tolerated
clinically in such a dosing regimen and provide the
opportunity to overcome or ameliorate the major clinical of
clinical problem of resistance to targeted therapies.
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Materials and methods
Compounds
Compounds were synthesised in-house or purchased from
AxonMedChem (Groningen, Netherlands), Active Biochem
(Kowloon, Hong Kong), Selleckchem (Boston, Massache-
setts, USA) or Tocris (Bristol, UK).
Cell culture models, assays and treatment
All cell lines were obtained from accredited cell banks,
validated by DNA proﬁling and conﬁrmed free of Myco-
plasma spp. by PCR. HCT116BAX−/−, HCT116BBC3−/− and
parent isogenic cell lines were obtained from Horizon
Discovery (UK). GI50 values (concentration that inhibits
cell proliferation by 50%) were determined by sulphurho-
damine blue staining [57]. Combination indices (CI) were
determined using median effect analysis [58]. Cells were
seeded in 96-well plates and at 2 days test compounds were
added at a ratio of 1:1 of their respective GI50 values. After
a further 4 days, cells were sulphurhodamine blue stained
and the CI calculated using Calcusyn (Biosoft, UK). A CI
value of 1 indicates an additive effect, <1 synergy and >1
antagonism. Longer term colony growth assay experiments
were performed in six-well plates. At the end of the
experiment cells were ﬁxed and stained using Crystal
Violet. Apoptosis was quantiﬁed by assaying cleavage of a
ﬂuorescent caspase 3/7 substrate (Promega, USA) and
autophagic cells were quantiﬁed using an LC3B immuno-
ﬂuorescence assay (Thermo Fisher Scientiﬁc, USA) [59].
Stable resistant lines were generated by incremental
exposure to inhibitors. Cells were passaged when they
reached conﬂuence and compound exposure increased until
the concentration reached 64 × GI50 or the solubility limit.
Reporter cells were generated by transfection with a plas-
mid encoding a cap-dependent ﬁreﬂy luciferase and an
EMCV IRES-driven Renilla luciferase (Promega, USA)
downstream of an EF1α promoter [60]. ERK2WT or ERK2Y36H
open reading frames were cloned into the expression vector
pEFIRES-P [60]. Cells were transfected using lipofectamine
(Thermo Fisher Scientiﬁc, USA) and cells with stable vector
incorporation selected with puromycin.
Cells were reverse transfected with targeting siRNAs or
positive or negative control siRNAs (Qiagen, Germany)
using hiperfect cationic lipid (Qiagen, Germany). Cells were
transfected in 96-well plates for viability assays or six-well
plates to conﬁrm the effects on target protein expression.
Analysis of gene expression
mRNA abundance was determined by RT-PCR using a
7900HT Fast Real-Time PCR System (Applied Biosystems,
USA). Levels of phosphorylated and total protein were
investigated by immunoblotting or ELISA (Mesoscale Dis-
covery, USA) [17, 59]. Antibodies were obtained from Cell
Signaling Technologies (AKTSER473-#4060, total-AKT-
#4691, BIM-#12450, BBC3-#2933, ERK1/2THR202/TYR204-
#9101, total-ERK1/2-#9102, p90RSKSER380-#11989, total-
p90RSK-#9355, PTEN-#5385; USA), or Merck (ERK2-#06–
333, GAPDH-#CB1001; Germany). EC50 values were cal-
culated from the ELISA data as the concentration that reduced
protein phosphorylation by half.
Next-generation whole-exome sequencing
Genomic DNA was extracted (Qiagen, Germany) and
exome capture performed using the SureSelect Human All
Exon V5 kit (Agilent, USA). Products were sequenced
using a paired end sequencing protocol (v1.5) on a HiSeq
2500 (Illumina, USA). Reads were aligned to the human
genome reference sequence GRCh37 using bwa [61].
Optical and PCR duplicates were marked in BAM ﬁles
using Picard 1.107 (http://picard.sourceforge.net), addi-
tional BAM ﬁle manipulations were performed using
Samtools (v0.1.18) and variant calling performed with
FreeBayes (v0.9.20–8) [62]. Data are available on the NCBI
Sequence Read Archive (SRA; https://www.ncbi.nlm.nih.
gov/sra) website under accession number SUB4997621.
ERK2 protein puriﬁcation and biochemical assay
To generate active ERK2WT or ERK2Y36H, GST-ERK2
(pCDFDuet-1) was coexpressed with constitutively active
MEK1S218E/S222E (pET-30b; Merck Chemicals Ltd, Ger-
many) in BL21-AI™ E. coli (Thermo Fisher Scientiﬁc,
USA). Active protein was puriﬁed over a GSTrap™ FF
column and digested with HRV 3C protease. Cleaved pro-
tein was puriﬁed with a HiLoad 16/600 Superdex 200 pg
column in series with 2 × 5 ml GSTrap™ FF columns fol-
lowed by a Mono Q® HR 5/5 column. All chromatography
columns were from GE Healthcare (UK).
ERK2 kinase activity was determined using an EZ
Reader II (PerkinElmer, USA). Conversion to product, and
inhibition, was calculated relative to no enzyme and all
reagent conditions. IC50 values (concentration that reduced
substrate conversion by half) were calculated using a four-
parameter logistics ﬁt (Dotmatics, UK).
Statistical analysis
Normal data distribution was determined using a D’Agos-
tino and Pearson normality test. Signiﬁcance for normally
distributed data was determined with a one-way ANOVA
and t test analyses and for non-normally distributed data
using a Kruskal−Wallis test. A false discovery rate
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(q value) for multiple testing was calculated using the
procedure of Benjamini, Krieger and Yekutieli (Graphpad,
USA).
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